An initiative of IBA Proton Therapy
Campus your proton
therapy community
  • Resource center
  • Training
  • Events
  • About
  • Log in
  • Resource center
  • Training
  • Events
  • About
  • Log in
An initiative of IBA Proton Therapy

Your results for

Filter by

Filter by
Results

Filter by

Content type
  • Event - Do not use (19)
  • Podcast (13)
  • Publications (652)
  • Training (6)
  • User case (13)
  • User meeting (21)
  • Webinar (119)
  • White paper (8)
Key content topics
Key audience
  • Newcomers (6)
Top cancer treatments
  • Brain and CNS (88)
  • Breast (59)
  • Gastro-intestinal (125)
  • Genito-urinary (51)
  • Gynecological (7)
  • Head and neck (133)
  • Hodgkin and Non-Hodgkin lymphoma (16)
  • Ocular (12)
  • Pediatric (100)
  • Reirradiation (12)
  • Sarcomas (18)
  • Thoracic (91)

Proton beam radiotherapy for pancreas cancer.

03/02/2020
/ Publications
/
Hypofractionation
Chemotherapy

A review article examined up to date data of PBT for pancreatic cancer. For both resectable and unresectable pancreatic cancer, the clinical outcome data is...

Proton beam radiotherapy for anal and rectal cancers.

03/02/2020
/ Publications
/
Hypofractionation

A review article looked at the current status of PBT for anal and rectal cancers. PBT offers appealing potential to reduce toxicity, increase patient compliance...

Proton beam re-irradiation for gastrointestinal malignancies: a systematic review.

03/02/2020
/ Publications
/
Reirradiation

A systematic review assessing for reports of proton-beam reirradiation for recurrent or second primary GI cancers. 7 included studies reported on proton-beam re...

Comparison of clinical outcomes between passive scattering versus pencil-beam scanning proton beam therapy for hepatocellular carcinoma.

03/03/2020
/ Publications
/
Survival

A study by the Samsung group from Korea published in the Green Journal. A total of 103 patients treated with proton therapy including 70 in the PS group and 33...

Proton beam therapy utilization in adults with primary brain tumors in the United States.

03/03/2020
/ Publications

Based on the National Cancer Database, a total of 1,296 patients received PBT from 2004 and 2015 for treatment of their primary brain tumor. High-grade glioma...

Late contrast enhancing brain lesions in proton treated low-grade glioma patients: clinical evidence for increased periventricular sensitivity and variable RBE.

03/03/2020
/ Publications

Late radiation-induced contrast enhancing brain lesions (CEBL) on MR images after proton therapy of brain tumors have been observed to occur frequently in...

Comparative analysis of acute toxicities and patient reported outcomes between intensity-modulated proton therapy (IMPT) and volumetric modulated arc therapy (VMAT) for the treatment of oropharyngeal cancer.

03/03/2020
/ Publications
/
IMPT
Chemotherapy
VMAT

This study compared 46 IMPT and 259 VMAT patients acute toxicities and reported that IMPT was associated with lower PEG-tube placement (p = 0.001) and less...

Patient Reported Outcomes Following Proton Pencil Beam Scanning vs. Passive Scatter/Uniform Scanning for Localized Prostate Cancer: Secondary Analysis of PCG 001-09.

03/03/2020
/ Publications
/
Pencil Beam Scanning - PBS

This study evaluated PROs with the Expanded Prostate Cancer Index Composite (EPIC) instrument for men with localized PC enrolled in PCG 001-09 (NCT01255748)...

End-of-Range Radiobiological Effect on Rib Fractures in Patients Receiving Proton Therapy for Breast Cancer.

03/03/2020
/ Publications

Published in the Red Journal, this MGH study looked into the possible causes to the high rate of rib fracture that reported in the recent MGH prospective trial...

Acute Toxicities After Proton Beam Therapy Following Breast-Conserving Surgery for Breast Cancer: Multi-institutional Prospective PCG Registry Analysis. This is the report of the prospective multi-institutional Proton Collaborative Group registry study.

03/04/2020
/ Publications

82 patients received PBT and their adverse events (AEs) were recorded prospectively at each institution. Median follow-up was 8.1 months. Median dose was 50.4...

Pagination

  • Previous page ‹
    • Page 19
    • Current page 20
    • Page 21
  • Next page ›
Campus
Subscribe to our newsletter
Follow us on
  • Facebook
  • Linkedin
  • Twitter
  • Youtube
Contact us
  • About Campus
  • Resources
  • Training
  • Connect
  • IBA Worldwide
  • Back to IBA Proton Therapy
Life Science
  • Legal
  • Terms of Use
  • Privacy policy
  • Cookies policy
  • Manage cookies
  • Code of conduct

Cookies policy

If you continue browsing this website, you agree to the use of cookies in order to provide you with services and offers tailored to your own interests.

Manage your cookie preferences

Respect for your privacy is still a priority for us at IBA.

Functional cookies ensure that the website runs smoothly. They cannot be turned off. By setting your preferences, you can turn the use of these cookies on and off on our website, although these settings will only be valid on the device you are currently using.

Accept all cookies
Adapt my preferences
Cookies policies